Having said this, we do note that in a systematic review and meta-analysis of randomized clinical trials, Xiao et al. concluded that while anti-VEGF agents do not improve the overall survival (OS) of patients with GBM, they do improve the progression-free survival (PFS) of these patients [43]. Here, VEGFA is linked to glioblastoma.